Beta Bionics (NASDAQ:BBNX) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Beta Bionics (NASDAQ:BBNX) from a sell rating to a hold rating in a report published on Saturday,Wall Street Zen reports.

BBNX has been the topic of several other research reports. William Blair started coverage on Beta Bionics in a research note on Friday, August 21st. They set a “market perform” rating on the stock. Bank of America lifted their target price on Beta Bionics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 15th. UBS Group reiterated a “buy” rating and issued a $25.00 price target on shares of Beta Bionics in a report on Tuesday. Leerink Partners upped their price target on Beta Bionics from $24.00 to $27.00 and gave the company an “outperform” rating in a research report on Monday, September 14th. Finally, Robert W. Baird raised their price objective on Beta Bionics from $14.00 to $16.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 15th. Seven equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Beta Bionics currently has a consensus rating of “Moderate Buy” and an average price target of $21.90.

Beta Bionics Price Performance

Shares of BBNX stock opened at $21.89 on Friday. The firm has a market cap of $984.83 million, a P/E ratio of -13.27 and a beta of 3.37. Beta Bionics has a 1-year low of $8.80 and a 1-year high of $32.71. The firm has a fifty day moving average of $17.66 and a two-hundred day moving average of $14.05.

Beta Bionics (NASDAQ:BBNX) last released its earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.09. The company had revenue of $32.01 million during the quarter. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. On average, sell-side analysts expect that Beta Bionics will post -2.06 EPS for the current year.

Insider Buying and Selling

In related news, insider Mike Mensinger sold 4,375 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total transaction of $83,606.25. Following the completion of the transaction, the insider owned 180,040 shares in the company, valued at $3,440,564.40. The trade was a 2.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Steven Russell sold 4,221 shares of the company’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $19.11, for a total value of $80,663.31. Following the transaction, the insider owned 169,628 shares of the company’s stock, valued at approximately $3,241,591.08. The trade was a 2.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 103,561 shares of company stock valued at $1,962,504 over the last three months. 5.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Beta Bionics

A number of hedge funds have recently added to or reduced their stakes in BBNX. Caitong International Asset Management Co. Ltd grew its position in shares of Beta Bionics by 1,075.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock worth $61,000 after acquiring an additional 1,818 shares during the last quarter. Legal & General Group Plc bought a new stake in Beta Bionics in the 2nd quarter valued at about $62,000. The Manufacturers Life Insurance Company bought a new stake in Beta Bionics in the 2nd quarter valued at about $172,000. ProShare Advisors LLC acquired a new position in Beta Bionics during the 4th quarter valued at about $217,000. Finally, Ieq Capital LLC bought a new position in Beta Bionics in the 2nd quarter worth about $229,000.

Key Stories Impacting Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: The FDA cleared Beta Bionics’ Mint patch pump, expanding its diabetes-device portfolio beyond the iLet Bionic Pancreas. A full U.S. launch is planned for the first quarter of 2027, potentially giving the company a second growth platform. Beta Bionics Stock Surges on FDA Clearance for Mint Patch Pump
• Positive Sentiment: Beta Bionics closed a public offering that generated $172.5 million in gross proceeds, including full exercise of the underwriters’ option. The capital should support Mint’s commercialization, manufacturing, research and development, and working capital needs. Beta Bionics Announces Closing of $172.5 Million Public Offering
• Positive Sentiment: Analyst sentiment remains broadly favorable. Recent price-target increases and a reported “Moderate Buy” consensus reflect optimism surrounding Mint and longer-term demand for automated insulin-delivery systems.
• Neutral Sentiment: Insiders Mark Hopman and Mike Mensinger sold shares under pre-arranged Rule 10b5-1 plans. The transactions totaled roughly $678,000 and do not necessarily indicate a change in management’s outlook, though they may affect sentiment. Beta Bionics Insider Trading
• Negative Sentiment: The equity offering issued millions of shares and pre-funded warrants at $17.25, creating dilution for existing shareholders and potentially limiting near-term upside.
• Negative Sentiment: Multiple law firms publicized a securities class action alleging inadequate disclosure of FDA Form 483 and warning-letter issues, including quality-management, patient-safety and customer-complaint concerns. The allegations remain unproven, but the litigation creates regulatory, reputational and financial uncertainty; the lead-plaintiff deadline is November 3, 2026. BBNX Securities Class Action Alert
• Negative Sentiment: Fiscal 2026 revenue guidance of $121 million to $126 million is below the approximately $133.9 million analyst consensus, signaling weaker near-term growth expectations.

Beta Bionics Company Profile

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.